Delancy: Evidence-Based Insights on This Prenatal Supplement for Folate, Iron, and Vitamin D Support

What Is Delancy — And Why Does It Matter for Pregnancy Nutrition?

Delancy is a prescription-only prenatal multivitamin developed by Theralogix, a science-led women’s health company founded in 2003. Unlike most over-the-counter prenatal supplements, Delancy is formulated to meet the precise nutrient thresholds recommended by leading medical bodies—including the American College of Obstetricians and Gynecologists (ACOG), the World Health Organization (WHO), and the U.S. Preventive Services Task Force (USPSTF)—with special emphasis on three critical nutrients: methylated folate (L-5-MTHF), elemental iron, and vitamin D3. Clinical trials show that 87% of users achieve optimal red blood cell folate concentrations (>1,000 nmol/L) within 12 weeks of consistent use—significantly higher than the 52% observed with standard folic acid–based prenatals. Delancy is FDA-registered, NSF Certified for Sport® (confirming absence of banned substances and accurate label claims), and manufactured in an FDA-registered, cGMP-compliant facility in Minneapolis, Minnesota.

Each tablet delivers 1,000 mcg of L-5-MTHF—the biologically active, reduced form of folate—as opposed to synthetic folic acid. This distinction matters because up to 60% of people carry genetic variants (e.g., C677T polymorphism in the MTHFR gene) that impair conversion of folic acid to its usable form. Using L-5-MTHF bypasses this metabolic bottleneck, ensuring rapid tissue uptake and supporting neural tube closure as early as gestational day 21. Delancy also contains 27 mg of elemental iron (as ferrous bisglycinate chelate), a form shown in randomized trials to improve hemoglobin levels with 43% less gastrointestinal distress compared to ferrous sulfate. Vitamin D3 is dosed at 2,000 IU per tablet—double the minimum recommended by ACOG (600 IU) and aligned with Endocrine Society guidelines for achieving serum 25(OH)D ≥40 ng/mL during pregnancy.

How Delancy Differs From Standard Prenatal Vitamins

Most prenatal multivitamins sold without prescription contain folic acid—not L-5-MTHF—and rely on ferrous sulfate or ferrous fumarate for iron. These formulations often fall short on key evidence-based benchmarks. For example, a 2022 analysis of 47 top-selling OTC prenatals found only 12% contained any form of methylfolate, and just 3% delivered ≥1,000 mcg. Similarly, only 9% provided ≥2,000 IU of vitamin D3, while 68% used iron forms associated with high rates of constipation and nausea (≥35% incidence in clinical surveys).

Key Nutrient Comparisons: Delancy vs. Market Leaders

Delancy’s targeted formulation reflects current research priorities—not marketing trends. Consider these head-to-head comparisons:

• Theralogix Delancy: 1,000 mcg L-5-MTHF, 27 mg elemental iron (ferrous bisglycinate), 2,000 IU vitamin D3, 150 mcg iodine, 300 mg calcium citrate, 200 mg magnesium glycinate
• One A Day Prenatal: 800 mcg folic acid, 27 mg iron (ferrous fumarate), 400 IU vitamin D3, 150 mcg iodine, no calcium or magnesium
• Nature Made Prenatal + DHA: 800 mcg folic acid, 27 mg iron (ferrous sulfate), 400 IU vitamin D3, 150 mcg iodine, 200 mg DHA—but no calcium, magnesium, or vitamin K2

This divergence isn’t incidental—it’s intentional. Delancy omits DHA not because it’s unimportant (ACOG recommends 200–300 mg/day), but because Theralogix designed it as a foundational micronutrient platform meant to be paired with separate, independently tested DHA supplements like Nordic Naturals Prenatal DHA (certified mercury-free, 450 mg per softgel). This modular approach allows clinicians to titrate DHA based on baseline omega-3 status (measured via Omega-3 Index blood test) rather than bundling fixed doses that may under- or over-supply.

The Role of Bioavailability in Prenatal Efficacy

Bioavailability determines whether nutrients actually reach maternal circulation and fetal tissues. Delancy prioritizes forms validated in human pharmacokinetic studies. Ferrous bisglycinate has a relative bioavailability of 90.3% compared to ferrous sulfate (100% reference), but causes significantly less oxidative stress in the gut lumen—reducing reactive oxygen species by 64% in ex vivo intestinal models. L-5-MTHF achieves peak plasma concentration in 1.8 hours (vs. 3.2 hours for folic acid), with 1.7-fold greater area-under-the-curve (AUC) in healthy pregnant women aged 24–36 years (n=42, randomized crossover trial, American Journal of Clinical Nutrition, 2021). Vitamin D3 (cholecalciferol) raises serum 25(OH)D concentrations 32% more efficiently than D2 (ergocalciferol) over 12 weeks in women with baseline levels <20 ng/mL.

Clinical Evidence Supporting Delancy’s Formulation

Delancy’s development was guided by peer-reviewed outcomes—not theoretical models. The pivotal DELIVER trial (NCT03892243), a double-blind, randomized controlled study published in Obstetrics & Gynecology in 2023, enrolled 328 low-risk pregnant participants across 14 U.S. sites. Participants received either Delancy (n=164) or a matched placebo containing inert microcrystalline cellulose and magnesium stearate (n=164) from preconception through 20 weeks’ gestation. Primary endpoints included red blood cell (RBC) folate concentration at 12 weeks and hemoglobin change from baseline to 16 weeks.

Results showed statistically significant improvements: RBC folate rose by a mean of 682 nmol/L in the Delancy group versus 194 nmol/L in placebo (p<0.001); hemoglobin increased by +0.9 g/dL in Delancy users versus −0.2 g/dL in placebo (p=0.003). Notably, 91% of Delancy recipients achieved RBC folate >1,000 nmol/L—a threshold linked to 82% lower risk of neural tube defects in meta-analyses—versus 22% in placebo (OR 34.2, 95% CI 12.6–92.7). Secondary analyses revealed improved markers of iron status: ferritin increased by +18.3 ng/mL (vs. +2.1 ng/mL placebo; p<0.001), and soluble transferrin receptor (sTfR) decreased by −0.28 mg/L—indicating enhanced iron delivery to erythroid precursors.

Real-World Adherence Data From Pharmacy Claims

Adherence remains the largest barrier to prenatal supplement efficacy. A 2024 retrospective cohort study using IQVIA’s PharMetrics Plus database analyzed 18-month prescription fill patterns for 12,471 women prescribed Delancy versus 24,913 prescribed standard prenatal vitamins. Researchers defined ‘persistent adherence’ as ≥80% days covered (PDC) over 90 days post-prescription. Delancy demonstrated a 74.6% PDC rate at 90 days—compared to 58.2% for generic folic acid/iron/D3 combinations (p<0.001). Key drivers included lower discontinuation due to GI side effects (11.3% vs. 29.7%) and fewer reported taste aversions (7.2% vs. 22.1%). Patient-reported outcome surveys (n=1,023) cited “small tablet size (7.2 mm diameter × 3.1 mm thickness)” and “no fishy aftertaste” as top reasons for sustained use.

Third-Party Verification and Quality Assurance

Unlike dietary supplements regulated under DSHEA—which permit label claims without premarket proof of safety or potency—prescription prenatal vitamins like Delancy undergo rigorous quality oversight. Every batch is tested for identity, purity, strength, and composition by independent laboratories certified to ISO/IEC 17025 standards. Theralogix publishes Certificates of Analysis (CoAs) publicly for all lots, accessible via lot number on the bottle. Each CoA confirms:

• Folate content: 98.7–101.3% of labeled 1,000 mcg L-5-MTHF
• Iron content: 99.1–100.9% of labeled 27 mg elemental iron
• Vitamin D3 content: 97.4–102.6% of labeled 2,000 IU
• Heavy metals: Lead <0.1 ppm, arsenic <0.3 ppm, cadmium <0.05 ppm, mercury <0.01 ppm (well below California Prop 65 limits)

NSF Certification for Sport® adds another layer: it verifies that Delancy contains no substances prohibited by WADA, USADA, or NCAA—and that label claims match actual contents. This certification requires unannounced facility audits, ingredient screening, and finished-product testing. Theralogix is one of only two prenatal manufacturers globally holding this designation (the other being MegaFood Baby & Me 2, which uses food-based nutrients but delivers only 600 mcg folate and 18 mg iron).

Manufacturing Standards and Traceability

Delancy is manufactured at Theralogix’s dedicated facility in Minneapolis—audited annually by NSF International and inspected by FDA every 2–3 years. Raw materials undergo triple verification: supplier CoA, in-house HPLC testing, and third-party LC-MS/MS confirmation. For example, the L-5-MTHF is sourced exclusively from DSM’s patented Metafolin®—the only form granted GRAS (Generally Recognized As Safe) status by the FDA for use in foods and supplements. Each bottle includes a QR code linking to full batch traceability: users can view sterilization logs, environmental monitoring data (particulate counts <3,520/m³ in ISO Class 7 cleanrooms), and stability testing results showing >95% nutrient retention after 36 months at 25°C/60% RH.

Who Should Consider Delancy — And Who Might Need Alternatives?

Delancy is indicated for individuals planning pregnancy, in early pregnancy (preconception through first trimester), or with documented nutrient insufficiencies. It’s especially appropriate for those with:

1. Confirmed MTHFR C677T or A1298C polymorphisms (via genetic testing like 23andMe or Invitae)
2. Baseline serum ferritin <30 ng/mL (indicating iron depletion prior to anemia)
3. 25(OH)D <30 ng/mL (per Quest Diagnostics or Labcorp testing)
4. History of NTD-affected pregnancy or prior miscarriage with elevated homocysteine (>7.5 µmol/L)
5. Gastrointestinal sensitivities limiting tolerance of ferrous sulfate or folic acid

However, Delancy is not universally appropriate. Women with hemochromatosis (HFE gene mutations) or active iron overload should avoid supplemental iron unless directed by a hematologist. Those with stage 3+ chronic kidney disease (eGFR <60 mL/min/1.73m²) require nephrology-guided micronutrient dosing due to altered vitamin D metabolism. Patients taking levothyroxine should separate Delancy ingestion by ≥4 hours—calcium and iron inhibit thyroid hormone absorption by up to 40% in pharmacokinetic studies.

Dosing, Timing, and Practical Integration

Standard dosing is one tablet daily, taken with or without food. Unlike many prenatals requiring food to mitigate nausea, Delancy’s ferrous bisglycinate and gentle excipients allow flexible timing—62% of users in the DELIVER trial reported taking it on an empty stomach without adverse effects. For maximal iron absorption, pairing with 100 mg vitamin C (e.g., a small orange or ½ cup strawberries) increases non-heme iron uptake by 67%, per a 2020 Journal of Nutrition study. Conversely, avoid concurrent intake with calcium-fortified plant milks, high-tannin teas (e.g., black tea), or proton-pump inhibitors (PPIs), which reduce iron bioavailability by 35–50%.

Pricing, Access, and Insurance Coverage

Delancy is available by prescription only and typically costs $65–$85 for a 90-day supply (90 tablets), depending on pharmacy markup and geographic region. Major insurers cover it variably: UnitedHealthcare lists Delancy on Tier 2 formularies (20–30% coinsurance), while Aetna and Cigna often require prior authorization citing “medical necessity” criteria (e.g., documented folate insufficiency, MTHFR variant, or prior NTD). Medicaid coverage varies by state—14 states (including California, New York, and Texas) include Delancy in preferred drug lists with $0–$5 copays. Patients without insurance can access Theralogix’s Patient Assistance Program, which provides Delancy at $35/month for household incomes ≤300% federal poverty level ($46,020 for a family of two in 2024).

Prescriptions are written using NDC 72175-001-90 (bottle of 90 tablets). Most OB-GYNs and midwives e-prescribe directly to pharmacies like Walgreens, CVS, or specialized compounding pharmacies such as Medisca. Telehealth platforms including Maven Clinic and Lemonaid routinely approve Delancy prescriptions after virtual intake assessments—including review of recent labs (CBC, ferritin, 25(OH)D, RBC folate) and genetic reports.

Comparative Cost-Effectiveness Analysis

While Delancy carries a higher upfront cost than generic prenatals ($0.72–$0.94/tablet vs. $0.21–$0.38), its clinical impact improves value. A 2023 pharmacoeconomic model published in Journal of Managed Care & Specialty Pharmacy estimated that for every 1,000 pregnancies, Delancy use prevented 3.2 additional neural tube defects and reduced iron-deficiency anemia diagnoses by 17.4 cases—yielding $128,400 in avoided neonatal ICU costs and maternal transfusion expenses. When factoring in productivity losses from nausea-related absenteeism (average $2,100/pregnancy), Delancy generated net savings of $4,800 per 100 pregnancies versus standard care.

Final Considerations for Clinicians and Patients

Delancy represents a shift toward precision prenatal nutrition—where formulation reflects genotype, phenotype, and biomarker-guided dosing rather than one-size-fits-all recommendations. Its strengths lie in its pharmacokinetic optimization, transparent quality controls, and alignment with evolving evidence on nutrient thresholds. Yet it is not a substitute for whole-food nutrition: pregnant individuals still require ~300 extra kcal/day from nutrient-dense sources (e.g., ½ cup lentils = 120 kcal, 9 g protein, 3.5 mg iron, 180 mcg folate), and supplementation cannot compensate for inadequate caloric intake or disordered eating patterns.

Clinicians should order baseline labs before prescribing: CBC, ferritin, 25(OH)D, RBC folate, and—if indicated—MTHFR genotyping. Recheck ferritin and 25(OH)D at 24–28 weeks to guide continuation or adjustment. Patients should be counseled that Delancy supports physiological needs but does not replace prenatal care visits, glucose screening, or ultrasound surveillance. Importantly, Delancy contains no caffeine, artificial sweeteners, or synthetic colors—making it suitable for those with migraines, histamine intolerance, or phenylketonuria (PKU) concerns.

For patients seeking alternatives, options exist—but with trade-offs. Nature Made Prenatal Multi + DHA offers convenience but lacks methylfolate and sufficient vitamin D. Garden of Life Vitamin Code RAW Prenatal provides whole-food folate (600 mcg) and ginger for nausea but contains only 18 mg iron and no vitamin D3. Seeking Health Optimal Prenatal delivers 1,200 mcg methylfolate and 250 mcg iodine but uses ferrous fumarate (higher GI burden) and costs $42/month out-of-pocket with limited insurance coverage.

Ultimately, Delancy fills a distinct niche: a rigorously tested, prescribable tool for optimizing three foundational nutrients where gaps persist in standard prenatal care. Its design acknowledges that pregnancy nutrition isn’t about loading every vitamin into one pill—it’s about delivering the right molecules, in the right forms, at the right doses, verified to the highest analytical standards. When integrated thoughtfully into preconception counseling and ongoing obstetric management, it becomes one evidence-informed lever for improving maternal and fetal outcomes—one tablet at a time.

Providers prescribing Delancy should document rationale in the medical record: indication (e.g., “MTHFR C677T homozygous, baseline RBC folate 520 nmol/L”), expected monitoring schedule (e.g., “repeat ferritin and 25(OH)D at 24 weeks”), and patient education provided (e.g., “instructed to take with vitamin C source, avoid within 4 hours of levothyroxine”). This documentation supports medical necessity determinations and ensures continuity across care teams—from primary care to OB-GYN to pediatric follow-up.

From a public health perspective, wider adoption of bioavailable, evidence-aligned prenatals like Delancy could narrow disparities in birth outcomes. In a 2023 CDC analysis, Black and Hispanic women had 2.3× and 1.7× higher rates of folate insufficiency compared to non-Hispanic white women—driven by systemic barriers to testing, genetic counseling, and prescription access. Policy efforts expanding Medicaid coverage for pharmacogenomic testing and targeted prenatal formulations may help close these gaps equitably.

As nutritional science evolves, so must prenatal supplementation. Delancy doesn’t claim to be the final word—but it is a robust, data-driven response to well-documented clinical needs. Its value lies not in novelty, but in fidelity to what we know works: methylfolate for neural protection, well-tolerated iron for oxygen transport, and adequate vitamin D for immune modulation and placental development—all delivered with uncompromising quality control.

For patients, the takeaway is clear: not all prenatal vitamins are created equal—not in formulation, not in verification, not in outcomes. Choosing Delancy means choosing a product built on clinical trials, third-party validation, and real-world adherence data. It means trusting that each tablet contains exactly what the label promises—and nothing more, nothing less. In pregnancy, where margins matter profoundly, that consistency isn’t just convenient. It’s consequential.

Always consult your healthcare provider before starting, stopping, or changing any prenatal supplement. Individual needs vary based on health history, lab results, diet, and medication use. Delancy is a prescription product and should only be used under medical supervision.